Cidara Therapeutics Inc [CDTX] stock prices are up 0.61% to $96.34 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CDTX shares have gain 8.76% over the last week, with a monthly amount glided 51.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning an Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
The stock price of Cidara Therapeutics Inc [CDTX] has been fluctuating between $10.14 and $99.00 over the past year. Currently, Wall Street analysts expect the stock to reach $141.75 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $96.34 at the most recent close of the market. An investor can expect a potential return of 47.14% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
The Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 94.24 points at the first support level, and at 92.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 99.46, and for the 2nd resistance point, it is at 102.58.
Ratios To Look Out For
It’s worth pointing out that Cidara Therapeutics Inc [NASDAQ:CDTX]’s Current Ratio is 16.45. Also, the Quick Ratio is 16.45, while the Cash Ratio stands at 15.8.
Transactions by insiders
Recent insider trading involved Davarpanah Nicole Negar, Chief Medical Officer, that happened on Sep 11 ’25 when 474.0 shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Jun 26 ’25 to buy 2.27 million shares. Meanwhile, Director Mineo Chrysa bought 2270.0 shares on Jun 02 ’25.